J
Jan Fourie
Researcher at University of Dundee
Publications - 14
Citations - 1680
Jan Fourie is an academic researcher from University of Dundee. The author has contributed to research in topics: Efavirenz & Rilpivirine. The author has an hindex of 12, co-authored 14 publications receiving 1569 citations.
Papers
More filters
Journal ArticleDOI
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Pedro Cahn,Anton Pozniak,Horacio Mingrone,Andrey Shuldyakov,Carlos Brites,Jaime Andrade-Villanueva,Gary Richmond,Carlos Beltran Buendia,Jan Fourie,Moti Ramgopal,Debbie Hagins,Franco Felizarta,José Valdez Madruga,Tania Reuter,Tamara Newman,Catherine B. Small,John Lombaard,Beatriz Grinsztejn,David Dorey,Mark R. Underwood,Sandy Griffith,Sherene Min +21 more
TL;DR: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravIR in this treatment-experienced patient group.
Journal ArticleDOI
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Roberto Ortiz,Edwin DeJesus,Homayoon Khanlou,Evgeniy Voronin,Jan van Lunzen,Jaime Andrade-Villanueva,Jan Fourie,Sandra De Meyer,Martine De Pauw,Eric Lefebvre,Tony Vangeneugden,Sabrina Spinosa-Guzman +11 more
TL;DR: DRV/r 800/100 mg qd was non-inferior to LPV/ r 800/200 mg at 48 weeks, with a more favorable safety profile, and offers a new effective and well tolerated once-daily, first-line treatment option for treatment-naive patients.
Journal ArticleDOI
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Calvin J. Cohen,Jaime Andrade-Villanueva,Bonaventura Clotet,Jan Fourie,Margaret Johnson,Kiat Ruxrungtham,Hao Wu,Carmen Zorrilla,Herta Crauwels,Laurence T. Rimsky,Simon Vanveggel,Katia Boven +11 more
TL;DR: Despite a slightly increased incidence of virological failures, a favourable safety profile and non-inferior efficacy compared with efavirenz means that rilpivirine could be a new treatment option for treatment-naive patients infected with HIV-1.
Journal ArticleDOI
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials
Calvin J. Cohen,Jean-Michel Molina,Pedro Cahn,Bonaventura Clotet,Jan Fourie,Beatriz Grinsztejn,Hao Wu,Margaret A. Johnson,Michael S. Saag,Khuanchai Supparatpinyo,Herta Crauwels,Eric Lefebvre,Laurence T. Rimsky,Simon Vanveggel,Peter Williams,Katia Boven +15 more
TL;DR: Rilpivirine had more virologic failures and improved tolerability versus efavirenz, and development of resistance in both groups; the effects onVirologic failure were more apparent with rilpavirine.
Journal ArticleDOI
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Pedro Cahn,Jan Fourie,Beatriz Grinsztejn,Sally Hodder,Jean-Michel Molina,Kiat Ruxrungtham,Cassy Workman,Tom Van De Casteele,Piet De Doncker,Erkki Lathouwers,Frank Tomaka +10 more
TL;DR: Once-daily DRV/r 800/100 mg was noninferior in virologic response to twice-daily Darunavir/ritonavir 600/ 100 mg at 48 weeks in treatment-experienced patients with no DRV RAMs, and with a more favorable lipid profile.